Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices

References

1. 1.↵
   Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. http://goldcopd.org. Accessed February 20, 2018.
2. 2.↵
   1. Dolovich MB,
   2. Dhand R

   . Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377(9770):1032–1045.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Pirozynski M,
   2. Sosnowski TR

   . Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv 2016;13(11):1559–1571.

   OpenUrl
4. 4.↵
   1. Hernandez P,
   2. Balter MS,
   3. Bourbeau J,
   4. Chan CK,
   5. Marciniuk DD,
   6. Walker SL

   . Canadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient reality. Can Respir J 2013;20(2):97–105.

   OpenUrlPubMed
5. 5.↵
   1. Menezes AM,
   2. Landis SH,
   3. Han MK,
   4. Muellerova H,
   5. Aisanov Z,
   6. van der Molen T,
   7. et al

   . Continuing to confront COPD international surveys: comparison of patient and physician perceptions about COPD risk and management. Int J Chron Obstruct Pulmon Dis 2015;10:159–172.

   OpenUrl
6. 6.↵
   1. Melani AS,
   2. Zanchetta D,
   3. Barbato N,
   4. Sestini P,
   5. Cinti C,
   6. Canessa PA,
   7. et al

   . Inhalation technique and variables associated with misuse of conventional metered dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93:439–446.

   OpenUrlPubMedWeb of Science
7. 7.
   1. Melani AS,
   2. Bonavia M,
   3. Cilenti V,
   4. Cinti C,
   5. Lodi M,
   6. Martucci P,
   7. et al

   . Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6):930–938.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Restrepo RD,
   2. Alvarez MT,
   3. Wittnebel LD,
   4. Sorenson H,
   5. Wettstein R

   . Medication adherence issues in patients treated for COPD. Int J COPD 2008;3(3):371–384.

   OpenUrl
9. 9.↵
   1. Jung E,
   2. Pickard AS,
   3. Salmon JW,
   4. Bartle B,
   5. Lee TA

   . Medication adherence and persistence in the last year of life in COPD patients. Respir Med 2009;103(4):525–534.

   OpenUrlPubMed
10. 10.↵
    1. Rau JL

    . Practical problems with aerosol therapy in COPD. Respir Care 2006;51(2):158–172.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Georges CA,
    2. Bolton LB,
    3. Bennett C

    . Functional health literacy: an issue in African-American and other ethnic and racial communities. J Natl Black Nurses Assoc 2004;15(1):1–4.

    OpenUrlPubMed
12. 12.↵
    1. Bourbeau J,
    2. Bartlett SJ

    . Patient adherence in COPD. Thorax 2008;63(9):831–838.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Hernandez P,
    2. Blater M,
    3. Bourbeau J,
    4. Hodder R

    . Living with chronic obstructive pulmonary disease: A survey of patient's knowledge and attitudes. Respir Med 2009;103(7):1004–1012.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Moreo K,
    2. Greene L,
    3. Sapir T

    . Improving interprofessional and coproductive outcomes of care for patients with chronic obstructive pulmonary disease. BMJ Qual Improv Rep 2016;5:u210329.w4679. doi: 10.1136/bmjquality.u210329.w4679.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Braman SS,
    2. Carlin BW,
    3. Hanania NA,
    4. Mahler DA,
    5. Ohar JA,
    6. Pinto-Plata V,
    7. et al

    . Results of a pulmonologist survey regarding knowledge, attitudes and practices with inhalation devices for COPD. Respir Care 2018;63(7):840–848.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Han MK,
    2. Martinez CH,
    3. Au DH,
    4. Bourbeau J,
    5. Boyd CM,
    6. Branson R,
    7. et al

    . Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet 2016;4(6):473–526.

    OpenUrl
17. 17.↵
    Code of Federal Regulations, Title 45, Part 46. Protection of human subject. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed February 21, 2018.
18. 18.↵
    1. Eysenbach G

    . Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res 2004;6(3):e34.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Seemungal TA,
    2. Hurst JR,
    3. Wedzicha JA

    . Exacerbation rate, health status and mortality in COPD–a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009;4:203–223.

    OpenUrlPubMed
20. 20.↵
    1. Hurst JR,
    2. Vestbo J,
    3. Anzueto A,
    4. Locantore N,
    5. Müllerova H,
    6. Tal-Singer R,
    7. et al

    . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128–1138.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Han MK,
    2. Quibrera PM,
    3. Carretta EE,
    4. Barr RG,
    5. Bleecker ER,
    6. Bowler RP,
    7. et al

    . Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Respir Med 2017;5(8):619–626.

    OpenUrl
22. 22.↵
    1. Kessler R,
    2. Ståhl E,
    3. Vogelmeier C,
    4. Haughney J,
    5. Trudeau E,
    6. Löfdahl CG,
    7. Partridge MR

    . Patient understanding, detection, and experience of COPD exacerbations. Chest 2006;130(1):133–142.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    COPD Foundation. COPD Foundation releases groundbreaking COPE survey results: low patient awareness about COPD exacerbations poses barrier to effective management. http://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/ID/256/COPD-Foundation-Releases-Groundbreaking-COPE-Survey-Results-Low-Patient-Awareness-About-COPD-Exacerbations-Poses-Barrier-to-Effective-Management.aspx. Accessed February 21, 2018.
24. 24.↵
    1. Sharafkhaneh A,
    2. Wolf RA,
    3. Goodnight S,
    4. Hanania NA,
    5. Make BJ,
    6. Tashkin DP

    . Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD 2013;10(4):482–492.

    OpenUrl
25. 25.↵
    1. Bellia V,
    2. Battaglia S,
    3. Matera MG,
    4. Cazzola M

    . The use of bronchodilators in the treatment of airway obstruction in elderly patients. Pulm Pharmacol Ther 2006;19(5):311–319.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Blau H,
    2. Mussaffi H,
    3. Mei Zehav M,
    4. Prais D,
    5. Livne M,
    6. Czitron BM,
    7. Cohen HA

    . Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007;33(4):491–495.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. O'Malley CA

    . Device cleaning and infection control in aerosol therapy. Respir Care 2015;60(6):917–927.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Standaert TA,
    2. Morlin GL,
    3. Williams-Warren J,
    4. Joy P,
    5. Pepe MS,
    6. Weber A,
    7. Ramsey BW

    . Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998(2):114:577–586.

    OpenUrlCrossRefPubMed